Overview

An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of Sinusitis

Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
Primary Objective: To evaluate the efficacy of dupilumab (SAR231893/REGN668) in the treatment of bilateral Nasal Polyposis (NP) by assessment of the endoscopic nasal polyp score (NPS) in comparison to placebo. Secondary Objectives: To evaluate effect of dupilumab with regards to: - symptoms of sinusitis, - sinus computed tomography (CT) scan, - NPS in the sub-group of participants with co-morbid asthma, - Safety and tolerability.
Phase:
Phase 2
Details
Lead Sponsor:
Sanofi
Collaborator:
Regeneron Pharmaceuticals
Treatments:
Antibodies, Monoclonal
Mometasone Furoate